{"entity":{"id":"nr4a2","kind":"target","name":"NR4A2","aka":["nuclear receptor subfamily 4 group A member 2","Nuclear receptor subfamily 4 group A member 2","TINUR","RNR1","HZF-3","NURR1"],"tldr":"NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","summary":"Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons.\n\nCIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Gemcitabine and C-DIM 12.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:7981","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7981"},{"label":"UniProt P43354","url":"https://www.uniprot.org/uniprotkb/P43354/entry"},{"label":"NCBI Gene 4929","url":"https://www.ncbi.nlm.nih.gov/gene/4929"},{"label":"Ensembl ENSG00000153234","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153234"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"NR4A2","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:7981","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7981","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P43354","url":"https://www.uniprot.org/uniprotkb/P43354/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene NR4A2","url":"https://civicdb.org/features/3996","note":"3 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA NR4A2: RNA tissue enhanced (adrenal gland 125 nTPM, bone marrow 126 nTPM, ovary 122 nTPM); no normal tissue stained high; highest cancer staining head and neck cancer (3 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Pancreatic ductal adenocarcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas NR4A2 tissue","url":"https://www.proteinatlas.org/ENSG00000153234-NR4A2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000153234 associations","url":"https://platform.opentargets.org/target/ENSG00000153234/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:7981","ensembl":"ENSG00000153234","uniprot":"P43354","entrez":"4929","firstDescribed":1994,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Mages H.W. et al, Mol. Endocrinol, 1994, \"NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7877627/","biology":"Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons. Location: Cytoplasm; Nucleus (UniProt). Locus 2q24.1 (HGNC).","whereFound":["Pancreatic ductal adenocarcinoma: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/nr4a2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}